论文部分内容阅读
目的分析格列美脲治疗2型糖尿病安全性及有效性。方法 2型糖尿病未经治疗的78例患者,随机分为两组,每组39例,一组给予格列美脲治疗,设为治疗组;一组给予格列吡嗪治疗,设为对照组,比较分析格列美脲临床药用价值。结果治疗组不良反应总发生率为17.95%,对照组为51.28%,结果差异具有统计学意义(P<0.05)。治疗组治疗后餐后2 h血糖与总胆固醇水平分别约降低4.0 mmol/L、2.42 mmol/L,降糖降脂效果显著,与治疗前比较差异具有统计学意义(P<0.05)。对照组与治疗组用药前后各项数值变化都较大,降糖、降脂效果明显,但两组结果差异无统计学意义(P>0.05)。结论格列美脲治疗2型糖尿病疗效确切,副作用小,值得临床推广使用。
Objective To analyze the safety and efficacy of glimepiride in the treatment of type 2 diabetes. Methods A total of 78 untreated patients with type 2 diabetes were randomly divided into two groups (n = 39 in each group). One group was treated with glimepiride and the other was treated with glipizide. The patients in control group , Comparative analysis of glimepiride clinical medicinal value. Results The total incidence of adverse reactions was 17.95% in the treatment group and 51.28% in the control group, the difference was statistically significant (P <0.05). After treatment, the blood glucose and total cholesterol in the treatment group decreased by about 4.0 mmol / L and 2.42 mmol / L respectively at 2 h, and the blood glucose and lipid-lowering effect was significant. The difference was statistically significant (P <0.05). Before and after treatment, the values in the control group and the treatment group changed greatly, and the hypoglycemic and lipid-lowering effects were obvious. However, there was no significant difference between the two groups (P> 0.05). Conclusion Glimepiride is effective in treating type 2 diabetes mellitus with small side effects and is worthy of clinical promotion.